Women with hormone-positive metastatic breast cancer face critical treatment decisions after initial chemotherapy stabilizes their disease. The choice of maintenance therapy can determine whether remission lasts months or years, fundamentally altering quality of life and long-term prognosis.
The FAMILY trial directly compared two maintenance approaches in 210 patients whose tumors had responded to first-line treatment. Fulvestrant, a selective estrogen receptor degrader, delivered median progression-free survival of 17.3 months compared to 9.0 months for capecitabine chemotherapy—representing a 37% reduction in disease progression risk. This 8.3-month difference occurred despite both treatments targeting the same patient population at identical disease stages.
This finding challenges current oncology practice where capecitabine often serves as standard maintenance chemotherapy. The safety profile strongly favored fulvestrant, with severe adverse events occurring in under 3% of patients versus 10.5% receiving capecitabine. No fulvestrant patients discontinued treatment due to toxicity, while nearly 8% of capecitabine patients required discontinuation.
For the broader cancer treatment landscape, this represents a paradigm shift toward hormone-targeted maintenance over traditional cytotoxic approaches in hormone-driven cancers. The trial's Chinese population may limit immediate global applicability, though the biological mechanisms should translate across ethnicities. The study's open-label design introduces potential bias, though objective progression measurements minimize this concern. Most significantly, overall survival data remain immature, leaving the ultimate clinical benefit unclear. This represents confirmatory evidence for fulvestrant's role, potentially establishing it as preferred maintenance therapy for this specific breast cancer subtype.